['type 2 diabetes mellitus']
['insulin glargine (u300)']

        Inclusion criteria:

          -  Patients with type 2 diabetes mellitus.

          -  Patients who are ≥18 years of age.

          -  Treated for diabetes for at least 6 months.

               -  If on basal insulin, stable for at least 3 months prior to screening visit on
                  their basal insulin treatment(s) (±20% total insulin dose)

               -  If on NIAHA, stable for at least 8 weeks prior to screening visit on their
                  NIAHA(s) (no change in dose or initiation of new NIAHAs).

          -  Patients on uncontrolled basal insulin (insulin glargine, normal protamine Hagedorn
             [NPH], detemir) +/ NIAHAs with an A1c >7.0% and ≤10% or uncontrolled on NIAHAs
             (insulin naïve patients) with an A1c >7.0% and ≤11%.

          -  Signed informed consent form.

        Exclusion criteria:

          -  Patients with type 1 diabetes mellitus (T1DM).

          -  Nightshift worker.

          -  Female patients who are pregnant or lactating.

          -  Treatment with an insulin other than basal insulin (premixes, rapid insulin, fast
             acting insulin analogues) within the previous 3 months.

          -  Patients with less than 1 year history of diabetes.

          -  Patients unwilling to inject insulin or perform self-monitoring blood glucose.

          -  Current alcohol or drug abuse.

          -  Patients unlikely to comply with the protocol and complete the study eg, uncooperative
             attitude, inability to return for follow-up visits.

          -  Patients with active cancer or any other diseases or conditions which in the opinion
             of the Investigator would make the patient unsuitable for participation in the study.

          -  Any clinically significant laboratory findings that in the judgment of the
             Investigator would preclude safe completion of the study.

          -  Known allergies to study drugs.

          -  Participation in another clinical study.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      